ReviewBioengineering & translational medicine2018
Clinical translation of microbe-based therapies: Current clinical landscape and preclinical outlook.
Review in Bioengineering & translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessing the long-term effects of microbial therapeutics as treatment within psychiatry: a systematic review.Frontiers in psychiatry · 2025Pooled it
- Harnessing the Vaginal Microbiome: A New Frontier in the Prevention of Sexually Transmitted Infections.Expert reviews in molecular medicine · 2026Review
- Bacterial Systems as a Precision Delivery Platform of Therapeutic Peptides for Cancer Therapy.Polymer science & technology (Washington, D.C.) · 2025Review
- Developing anACS pharmacology & translational science · 2025Article
- How Can 'Health in All Policies' Help Maximise the Potential of Microbial Biotechnologies for Health, Equity and Sustainability?Microbial biotechnology · 2025Review
- Engineered Tissue Models to Decode Host-Microbiota Interactions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Microbes Saving Lives and Reducing Suffering.Microbial biotechnology · 2025Article
- Feasibility of engineeredBioengineering & translational medicine · 2024Article
- The emerging tumor microbe microenvironment: From delineation to multidisciplinary approach-based interventions.Acta pharmaceutica Sinica. B · 2024Review
- Mechanisms and Clinical Implications of Human Gut Microbiota-Drug Interactions in the Precision Medicine Era.Biomedicines · 2024Review
- Smart nanoparticles for cancer therapy.Signal transduction and targeted therapy · 2023Review
- Weaponising microbes for peace.Microbial biotechnology · 2023Article
- Micro and nanotechnologies: The little formulations that could.Bioengineering & translational medicine · 2023Review
- In vitro assembly of plasmid DNA for direct cloning in Lactiplantibacillus plantarum WCSF1.PloS one · 2023Article
- Engineered microorganism-based delivery systems for targeted cancer therapy: a narrative review.Biomaterials translational · 2022Review
- Polymer and Crosslinker Content Influences Performance of Encapsulated Live Biotherapeutic Products.Cellular and molecular bioengineering · 2021Article
- The evolution of commercial drug delivery technologies.Nature biomedical engineering · 2021Review
- Design of synthetic human gut microbiome assembly and butyrate production.Nature communications · 2021Article
- Modulating Oral Delivery and Gastrointestinal Kinetics of Recombinant Proteins via Engineered Fungi.The AAPS journal · 2021Article
- Cell therapies in the clinic.Bioengineering & translational medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Next generation microbe-based therapeutics, inspired by the success of fecal microbiota transplants, are being actively investigated in clinical trials to displace or eliminate pathogenic microbes to treat various diseases in the gastrointestinal tract, skin, and vagina. Genetically engineered microbes are also being investigated in the clinic as drug producing factories for biologic delivery, which can provide a constant local source of drugs. In either case, microbe-therapeutics have the opportunity to address unmet clinical needs and open new areas of research by reducing clinical side effects associated with current treatment modalities or by facilitating the delivery of biologics. This review will discuss examples of past and current clinical trials that are investigating microbe-therapeutics, both microbiome-modulating and drug-producing, for the treatment of a range of diseases. We then offer a perspective on how preclinical approaches, both those focused on developing advanced delivery systems and those that use in vitro microbiome model systems to inform formulation design, will lead to the realization of next-generation microbe-therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.